Stocks
SLS Stock Jumps on Optimistic Comments from Healthcare Execs
Sellas Life Sciences (SLS) shares rose 2% overnight after healthcare executives called its acute myeloid leukemia (AML) drug a potential game changer.
AstraZeneca's Michael Anglestein and Johnson & Johnson product director Michael Frascello were among those who expressed optimism about the Regal trial, which has recorded 78 of the required 80 events to trigger its final efficacy analysis.
Regal aims to produce a median overall survival rate of 12.6 months, compared with eight months for the control arm. Positive results could lead to a biologics license application to the FDA.